[Unconventional hemodiafiltration: double-high-flux and push-pull]

Area of Science:

• Nephrology
• Biomedical Engineering
• Clinical Medicine

Context:

• End-stage renal disease (ESRD) patients exhibit significant morbidity and mortality linked to the retention of large uremic toxins, such as beta-2 microglobulin.
• Standard hemodialysis (HD) is often insufficient for removing these larger solutes, leading to complications like dialysis-associated amyloidosis.
• On-line hemodiafiltration (OL-HDF) is effective but costly, necessitating exploration of alternative efficient treatments.

Purpose:

• To evaluate the efficacy of double high-flux hemodiafiltration (DHF-HDF) and push-pull hemodiafiltration (PP-HDF) in removing larger uremic toxins and mitigating dialysis-associated amyloidosis.
• To assess the potential of DHF-HDF and PP-HDF as cost-effective alternatives to OL-HDF, particularly regarding the need for ultrapure substitution fluid.

Summary:

• DHF-HDF utilizes two series-connected high-flux dialyzers for combined diffusion and convection, followed by backfiltration, mimicking post-dilution OL-HDF.
• PP-HDF employs a high-flux membrane and double-pump system for alternating rapid convection and backfiltration of sterile dialysate.
• Both DHF-HDF and PP-HDF require high blood flow rates and demonstrate enhanced removal of middle molecules, reducing symptoms of dialysis-related amyloidosis.

Impact:

• These advanced hemodiafiltration techniques show promise in improving patient outcomes by more effectively clearing uremic toxins.
• Successful implementation of DHF-HDF and PP-HDF could lead to reduced healthcare costs associated with managing dialysis-associated amyloidosis complications.
• The findings support the clinical utility of DHF-HDF and PP-HDF as efficient and potentially more accessible treatment options for ESRD patients.